Skip to main content

Month: March 2023

Integer Schedules First Quarter 2023 Earnings Release and Conference Call for April 27, 2023

PLANO, Texas, March 30, 2023 (GLOBE NEWSWIRE) — Integer Holdings Corporation (NYSE:ITGR) announced today that it plans to release financial and operational results for first quarter 2023, at 7 a.m. Central Time (CT) / 8 a.m. Eastern Time (ET) on Thursday, April 27, 2023. Following the release, Integer management will host a webcast at 8 a.m. CT / 9 a.m. ET to discuss these results. Other forward-looking and material information may also be discussed during this call. Conference call details:Date:  Thursday, April 27, 2023 Time:  8 a.m. CT / 9 a.m. ET Domestic dial-in number: (888) 330-3567 International dial-in number: (646) 960-0842 Conference ID:  9252310 Webcast Registration: ITGR Q1 2023 Earnings CallAn audio replay will be available for 7 days and can be accessed by dialing (800) 770-2030 or (647) 362-9199 and using Conference...

Continue reading

Uponor Infra sells its district energy business to ISOPLUS

Uponor Corporation, Investor News, 30 March 2023 at 15:00 EEST Uponor Infra sells its district energy business to ISOPLUS Uponor Corporation’s subsidiary, Uponor Infra Oy has today entered into an agreement to sell its district energy business to ISOPLUS Suomi Oy, part of ISOPLUS Group, a leading manufacturer of district heating pipes in Europe. The sale agreement includes Uponor’s district energy businesses in Finland, Sweden, Estonia, and Norway as well as its district energy production located in Vaasa, Finland. The district energy business had a net sales level of approximately €40 million in 2022. The transaction will be completed on 31 March 2023. The value of the transaction is not disclosed. “The divestment is in line with Uponor Infra’s strategy that focuses on growing its core business. While district energy is an attractive...

Continue reading

Bufab Group: Bufab publishes Annual- and Sustainability Report for 2022

PRESSRELEASE, Värnamo 30 Mars 2023Bufab’s Annual- and Sustainability Report for 2022 is now available on the Group’s website www.bufabgroup.com. The financial year covers the period from 1 January to 31 December 2022.For further information, please contact: Marcus Söderberg, CFO, Bufab Group, telephone: +46 370 69 69 60This information is information that Bufab AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 14.00 CET on March 30, 2023.About BufabBufab AB (publ), Corporate Registration Number 556685-6240, is a trading company that offers its customers a full-service solution as Supply Chain Partner for sourcing, quality control and logistics for C-Parts (screws, nuts, etc.). Bufab’s Global Parts...

Continue reading

NAACP and TransUnion Unite to Provide Credit Education For All Stages of Life

BALTIMORE & CHICAGO, March 30, 2023 (GLOBE NEWSWIRE) — The NAACP and TransUnion (NYSE: TRU) announced today the launch of Connecting to Our Financial Future, a credit education website designed to promote financial inclusion among traditionally underserved and underrepresented communities. The announcement comes at a time when more than 45 million consumers in the U.S. are considered to be either credit unserved or underserved, meaning they have little to no credit products. Traditionally, members of the Black community and other historically marginalized communities have faced more challenges building credit histories and accessing loans at reasonable rates. The website, crafted specifically for these audiences, is designed to reach people where they are in their credit journey — whether just getting started, maintaining...

Continue reading

Sono-Tek Announces First Production Scale System Order Exceeding $600K From Specialty Clean Energy Customer, First Part of Expected Multi-System Program

Order Expected to be Shipped in Current Fiscal Year MILTON, NY, March 30, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Sono-Tek Corporation (Nasdaq: SOTK), the leading developer and manufacturer of ultrasonic coating systems, today announced that it has received a new order exceeding $0.6 million from a customer in the clean energy sector, the first part of an expected multi-phase program for additional systems. The clean energy customer initially purchased an R&D system from Sono-Tek for development and progressed to this order for a production scale system. Sono-Tek’s system applies a proprietary thin film on the customer’s product that is used in the green energy market.  The order is scheduled to ship during Sono-Tek’s current fiscal year ending February 2024. Future orders from this customer are expected after the successful...

Continue reading

IMUNON Reports 2022 Financial Results and Provides Business Update

Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., March 30, 2023 (GLOBE NEWSWIRE) — IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, today announced financial results for the year ended December 31, 2022, and provided an update on its clinical development programs with IMNN-001 (formerly GEN-1), a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for the treatment of advanced-stage ovarian cancer, and with PLACCINE, a proprietary, multivalent DNA plasmid technology utilizing synthetic, non-viral vaccine delivery vectors being evaluated in preclinical studies for superiority over current generation of nucleic acid vaccines. Highlights of 2022 and recent weeks include:Completed...

Continue reading

Galectin Therapeutics Reports 2022 Financial Results and Provides Business Update

NORCROSS, Ga., March 30, 2023 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2022. These results are included in the Company’s Annual Report on Form 10-K, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said: “As previously reported, we completed recruitment in late December 2022 and randomization by the end of February 2023 in our adaptively designed Phase 2b/3 NAVIGATE trial for the prevention of esophageal varices in patients with NASH cirrhosis with a total of 357 patients. We randomized more patients than we had...

Continue reading

Achieve Life Sciences Announces Refresh to Board of Directors

SEATTLE, Wash. and VANCOUVER, British Columbia, March 30, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced changes to the Company’s Board of Directors to continue to support the future direction of the Company. As provided in the previously reported Cooperation Agreement, as amended, between the Company and certain of its shareholders, Mr. Stuart Duty, Mr. Thomas King, and Mr. Tom Sellig have been appointed to the Board of Directors and will be nominated for election at the Company’s Annual Meeting of Stockholders to be held in June 2023. Additionally, each of Mr. Donald Joseph, Dr. Martin Mattingly, and Mr. Jay Moyes will not be nominated...

Continue reading

Theriva Biologics Reports Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results

– Dosed the first patient in VIRAGE, a Phase 2b clinical trial of systemically administered VCN-01 in combination with chemotherapy for Pancreatic Ductal Adenocarcinoma – – Dosed the first patient in the investigator sponsored Phase 1 clinical trial of VCN-01 for patients with brain tumors – – Presented positive safety and pharmacokinetic data from the ongoing Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant recipients at 2023 Tandem Meetings Transplantation & Cellular Therapy Meetings; Dosed the first patient in Cohort 2 – – As of December 31, 2022, Theriva Biologics reports $41.8 million in cash, which is expected to provide runway into the third quarter of 2024 – – Conference call and webcast to be held on Thursday, March 30th at 8:30 a.m. ET – ROCKVILLE, Md., March 30, 2023 (GLOBE...

Continue reading

H2O Innovation’s O&M Business Line Receives Recognition Awards

QUEBEC CITY, March 30, 2023 (GLOBE NEWSWIRE) — (TSX: HEO) – H2O Innovation Inc. (“H2O Innovation” or the “Corporation”) is proud to announce that its Operation and Maintenance (O&M) business line has received two recognition awards, which speak to the team’s continued dedicated service and great performance. For the third year in a row, the Corporation’s O&M contract with the City of Canton, GA, was honored with the Gold Award by the Georgia Association of Water Professionals (GAWP). This award recognizes exceptional performance in the delivery of safe drinking water and the protection of Georgia’s water resources, as this type of leadership is essential to a prosperous future for all Georgians. “Congratulations to H2O Innovation and all the staff at the water plant for continued outstanding service. This is well deserved,” stated...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.